List of Excipients in Branded Drug BUMEX

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Validus Pharmaceuticals LLC	BUMEX	bumetanide	30698-630	ANHYDROUS LACTOSE
Validus Pharmaceuticals LLC	BUMEX	bumetanide	30698-630	CELLULOSE, MICROCRYSTALLINE
Validus Pharmaceuticals LLC	BUMEX	bumetanide	30698-630	D&C YELLOW NO. 10
Validus Pharmaceuticals LLC	BUMEX	bumetanide	30698-630	FD&C BLUE NO. 1
Validus Pharmaceuticals LLC	BUMEX	bumetanide	30698-630	MAGNESIUM STEARATE
Validus Pharmaceuticals LLC	BUMEX	bumetanide	30698-630	STARCH, CORN
Validus Pharmaceuticals LLC	BUMEX	bumetanide	30698-630	TALC

BUMEX Excipient Strategy and Commercial Opportunities for Bumetanide

Last updated: August 5, 2026

Bumex is the branded product name for bumetanide, a loop diuretic used primarily to treat edema associated with congestive heart failure, hepatic disease, and renal disease. Bumetanide is an established, low-cost active pharmaceutical ingredient with no meaningful remaining new-drug exclusivity in the United States. Commercial value therefore depends on formulation performance, supply reliability, dosage-form differentiation, and targeted clinical positioning rather than basic molecule protection.

The strongest opportunities are oral products with improved swallowability, dose flexibility, lower tablet burden, and more reliable dissolution. Injectable products may support hospital contracts, while combination products and specialty delivery systems face greater regulatory and clinical barriers.

What is BUMEX and how is bumetanide used?

Bumex contains bumetanide, a potent loop diuretic that inhibits sodium and chloride reabsorption in the ascending limb of the loop of Henle. Oral tablets are generally used for chronic edema management. Intravenous and intramuscular products are used when rapid diuresis is required or oral administration is impractical.

Attribute	Bumetanide
Brand	Bumex
Active ingredient	Bumetanide
Drug class	Loop diuretic
Primary use	Edema associated with cardiac, hepatic, and renal disease
Common dosage forms	Tablets and injection
U.S. regulatory status	Established prescription drug
Competitive status	Generic competition
Key formulation issue	Low-dose uniformity and dose flexibility
Commercial barrier	Limited pricing power and mature market

Bumetanide is substantially more potent by weight than furosemide. That creates a formulation challenge because commercial tablets contain small quantities of active ingredient, particularly at the 0.5 mg strength. Content uniformity, blend segregation, and assay control are more important than they are for high-dose tablets.

What excipients are used in BUMEX formulations?

Public product labeling identifies conventional pharmaceutical excipients for Bumex dosage forms, including tablet fillers, binders, disintegrants, lubricants, and colorants. Exact inactive-ingredient composition can vary by manufacturer, strength, country, and dosage form. FDA labeling and the Inactive Ingredient Database should control any product-specific excipient assessment. [1,2]

Typical excipient functions for bumetanide tablets include:

Function	Candidate excipient classes	Commercial purpose
Diluent	Lactose, microcrystalline cellulose, mannitol, dibasic calcium phosphate	Provides tablet mass and improves handling
Binder	Pregelatinized starch, povidone, hypromellose	Improves granule and tablet strength
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Promotes tablet breakup
Lubricant	Magnesium stearate, sodium stearyl fumarate	Reduces sticking and ejection force
Glidant	Colloidal silicon dioxide	Improves powder flow
Colorant	Approved pigments or lakes	Supports strength identification
Film coating	Hypromellose, polyethylene glycol, titanium dioxide or permitted alternatives	Improves handling, appearance, and taste

The critical design issue is not the number of excipients. It is the interaction between low-dose bumetanide, powder flow, blend uniformity, compression, and dissolution.

Low-dose content uniformity

At 0.5 mg and 1 mg strengths, a formulation can contain a high proportion of excipient relative to active ingredient. Direct compression may be commercially attractive but can create segregation risk if particle sizes, densities, or surface properties differ materially.

Wet granulation may improve distribution and compressibility. It also adds process complexity and can affect the solid-state properties of bumetanide. Dry granulation can reduce moisture exposure but may require tighter control of ribbon density, milling, and granule size.

A robust development program should evaluate:

• Assay and content uniformity across the blend and finished tablets.
• Dissolution across relevant pH conditions.
• Blend segregation during transfer and hopper residence.
• Tablet hardness, friability, and disintegration.
• Stability under accelerated and long-term conditions.
• Extractables and leachables for coated or packaged products.
• Excipient compatibility, including moisture and peroxide sensitivity.

What excipient strategy is strongest for a generic BUMEX tablet?

The most defensible baseline strategy is a simple, conventional immediate-release tablet using well-established excipients. Regulatory familiarity reduces development risk and simplifies an abbreviated new drug application.

A practical platform could use microcrystalline cellulose or lactose as the principal diluent, a low level of binder, a superdisintegrant, colloidal silicon dioxide, and magnesium stearate or another established lubricant. The final selection should be driven by content uniformity and dissolution rather than by novelty.

Strategy 1: Conventional immediate-release tablet

This is the lowest-risk product architecture. It can target the established 0.5 mg, 1 mg, and 2 mg strengths associated with Bumex labeling and generic market demand.

Commercial advantages include:

• Straightforward manufacturing.
• Familiar excipient safety profiles.
• Low development cost.
• Compatibility with standard ANDA expectations.
• Broad pharmacy substitution potential.

The principal weakness is limited differentiation. Price competition can quickly reduce margins.

Strategy 2: Orally disintegrating or fast-dispersing tablet

An orally disintegrating tablet could improve administration for patients with dysphagia, frailty, acute illness, or limited access to water. Mannitol, crospovidone, croscarmellose sodium, and taste-masking technologies could support this approach.

The opportunity is clinically plausible but commercially narrower. Bumetanide has a strong pharmacologic effect at low doses, so taste and dose uniformity must be controlled carefully. An ODT may also require additional human-factors work, packaging protection, and comparative performance testing.

Strategy 3: Scored, flexible-dose tablet

Dose flexibility is particularly relevant for diuretics because prescribers often titrate therapy based on fluid status, renal function, weight, and response. A scored tablet can reduce tablet burden and improve dose adjustment.

The commercial value depends on score performance, subdivision uniformity, mechanical robustness, and regulatory labeling. A differentiated score design may have limited patent value but can improve prescriber and pharmacist acceptance.

Strategy 4: Oral liquid or unit-dose solution

An oral liquid could serve pediatric, geriatric, institutional, and feeding-tube populations. Important excipient issues include preservative selection, pH control, microbial stability, solubilization, and dosing-device accuracy.

This format has more meaningful lifecycle value than a standard tablet because it addresses administration needs that tablets do not solve. It also creates higher manufacturing and stability costs. A liquid product must avoid excipients that create avoidable risks in patients with renal impairment, electrolyte abnormalities, diabetes, or fluid restrictions.

What formulations are protected by BUMEX patents?

Bumetanide is an old small-molecule drug, and the original product patents and regulatory exclusivities have expired. Current commercial protection is unlikely to come from a broad composition-of-matter patent covering bumetanide itself.

Potentially relevant rights may instead involve:

• Specific oral liquid compositions.
• Taste-masked dosage forms.
• Orally disintegrating tablets.
• Modified-release systems.
• Combination products.
• Manufacturing processes.
• Specialized packaging or device systems.
• Method-of-use claims for defined patient populations.

These rights would need claim-by-claim assessment in the relevant jurisdiction. A new excipient combination does not automatically create meaningful patent protection. Patentability generally depends on novelty, non-obviousness, enablement, and commercially relevant claim scope.

A conventional lactose or microcrystalline-cellulose tablet is unlikely to support a durable blocking position. A formulation with a defined dissolution profile, stability advantage, clinically relevant administration benefit, or manufacturing solution has a stronger basis for patent filing, although enforcement value remains dependent on claim drafting and evidence.

When does BUMEX lose exclusivity and what is the generic status?

Bumex has already lost its practical U.S. market exclusivity. Bumetanide generics are available, and the active ingredient is not protected by current new-molecule exclusivity. FDA’s Orange Book lists approved drug products and relevant patent and exclusivity information, while Drugs@FDA provides approval records and labeling history. [3,4]

Exclusivity issue	Bumetanide status
New chemical entity exclusivity	Expired
Original molecule patent protection	Expired
Generic availability	Established
Paragraph IV exposure	Historically relevant only to any unexpired listed patent
Biosimilar pathway	Not applicable
Regulatory pathway for tablets	Generally ANDA-based
Current commercial moat	Manufacturing, supply, formulation, contracting, and distribution

What is the Orange Book status of BUMEX?

The Orange Book is the primary U.S. source for therapeutic-equivalence evaluations and listed patents or exclusivity associated with approved products. Bumetanide generic products are generally evaluated through the ANDA pathway and may receive an “A” therapeutic-equivalence rating when they meet FDA requirements against the relevant reference product. [3]

The commercial importance of Orange Book status is limited for a mature generic such as bumetanide. The main issues are:

1. Whether a reference-listed drug remains commercially active.
2. Whether an applicant can identify a suitable reference product.
3. Whether any listed patent remains relevant.
4. Whether the proposed product meets bioequivalence, dissolution, labeling, and manufacturing requirements.

Are there Paragraph IV challenges for BUMEX?

Paragraph IV litigation is not a central current risk for a conventional bumetanide tablet because the principal product and molecule protections have expired. A Paragraph IV certification could still arise if an applicant confronts a later-listed patent covering a formulation, method of use, or delivery system.

For a new differentiated product, the relevant risk shifts from challenging Bumex patents to defending the applicant’s own formulation patents against later entrants. Patent value would be higher where the product includes a clinically meaningful feature that is difficult to design around, such as a specific liquid stability profile or a device-integrated dosing system.

How strong is the BUMEX patent estate?

The legacy Bumex patent estate is weak as a current exclusionary platform because bumetanide is an established generic drug. The remaining competitive advantage is operational rather than patent-based.

Estate component	Relative strength
Bumetanide composition of matter	None for current commercial exclusion
Conventional tablet excipients	Low
Standard immediate-release process	Low to moderate
ODT or taste-masked product	Moderate if claims are narrow and validated
Oral liquid formulation	Moderate
Device-linked delivery system	Moderate, depending on claims
Manufacturing know-how	Potentially meaningful but difficult to enforce
Supply-chain qualification	Commercially meaningful

Trade secrets may protect process parameters, blend order, granulation endpoint, coating conditions, and packaging controls. These rights do not prevent independent development but can reduce manufacturing failures and improve cost performance.

What commercial opportunities exist for BUMEX excipients and formulations?

The most attractive opportunities are targeted products with a specific customer problem.

Hospital and institutional supply

An injectable bumetanide product can compete on supply reliability, vial configuration, preservative strategy, packaging, and contract pricing. Hospitals value continuity of supply because loop diuretics are routine inpatient medicines. A ready-to-administer presentation could reduce preparation time, but it would require validation of container closure, sterility, stability, and administration compatibility.

Specialty oral liquid

A unit-dose oral solution could target long-term-care facilities, home care, pediatric use, and patients unable to swallow tablets. Packaging and dosing-device accuracy would be central to the value proposition.

Generic-plus tablet

A scored, film-coated tablet with improved identification and consistent dissolution could support modest differentiation. The product would still face generic pricing pressure, but a reliable supply record and broad strength coverage could improve contracting outcomes.

Excipient supplier opportunity

Excipient manufacturers can support bumetanide developers with:

• Low-moisture diluents.
• Co-processed excipients for direct compression.
• High-functionality superdisintegrants.
• Taste-masking systems.
• Low-peroxide or low-reactivity excipient grades.
• Excipient systems designed for low-dose blend uniformity.
• Ready-to-use granulation platforms.

The strongest value proposition is process robustness, not a novel excipient name. Suppliers that can demonstrate improved content uniformity, lower tablet defects, or faster scale-up have a stronger commercial position.

How does BUMEX compare with furosemide?

Furosemide is the larger and more price-competitive loop-diuretic market. Bumetanide has a lower dose burden and is often selected when clinicians want a potent alternative to furosemide. That does not automatically create superior commercial economics.

Factor	Bumetanide	Furosemide
Dose by weight	Lower	Higher
Tablet development challenge	Low-dose uniformity	Higher tablet mass, broader dose range
Generic competition	Established	Very extensive
Liquid opportunity	Targeted	Broader established market
Brand differentiation	Limited	Limited
Hospital relevance	Meaningful	Very high
Excipient opportunity	Dose uniformity and administration	Dose range, liquids, and formulation convenience

A bumetanide product can compete where low-dose flexibility, administration convenience, or supply reliability matters. It is unlikely to compete successfully through price alone against the broad furosemide market.

What FDA regulatory requirements apply to a new BUMEX product?

A conventional generic tablet would generally require an ANDA demonstrating pharmaceutical equivalence and bioequivalence to the reference product. The application must address active ingredient identity, strength, dosage form, route, inactive ingredients, manufacturing controls, dissolution, stability, and labeling. FDA’s ANDA guidance and inactive-ingredient resources are central to development planning. [2,5]

A reformulated product with a new dosage form may require a different regulatory strategy. If the product cannot rely on the same therapeutic-equivalence framework as an established tablet, a 505(b)(2) application may be relevant. The regulatory path depends on the extent of formulation change and the reliance placed on FDA’s prior findings for bumetanide.

What generic launch risks exist for BUMEX?

The main launch risks are commercial and operational:

• Low reimbursement and rapid price erosion.
• Limited market size compared with furosemide.
• Reference-product sourcing difficulties.
• Low-dose content-uniformity failures.
• Dissolution variability after scale-up.
• Supply interruption for specialized excipients.
• Hospital purchasing concentration.
• Limited ability to obtain premium pricing without a clear clinical benefit.
• Regulatory delay from formulation changes.
• Thin margins for multiple tablet strengths.

A launch is more attractive when the developer controls reliable API supply, has efficient low-dose manufacturing, and can secure institutional or specialty-pharmacy contracts before approval.

Key Takeaways

• Bumex is the legacy brand for bumetanide, an established loop diuretic with generic competition.
• Original molecule and product exclusivities have expired.
• A conventional tablet has low patentability and limited pricing power.
• The main technical challenge is low-dose content uniformity, especially at 0.5 mg and 1 mg strengths.
• ODTs, scored tablets, oral liquids, and ready-to-administer injections offer the clearest formulation opportunities.
• Excipient selection should prioritize blend uniformity, dissolution, stability, and manufacturing scale-up.
• A 505(b)(2) pathway may be relevant for materially differentiated dosage forms.
• Biosimilar risk does not apply because bumetanide is a small-molecule drug.
• Commercial success depends more on supply reliability, institutional contracting, and administration benefits than on legacy Bumex patent rights.

FAQs About Bumex Excipient and Formulation Opportunities

Can a new excipient combination create a patent for bumetanide?

Yes, but only if the claimed combination meets patentability standards and provides a non-obvious technical or clinical advantage. A routine substitution of lactose, cellulose, starch, or magnesium stearate is unlikely to create strong exclusionary rights.

Is bumetanide suitable for an orally disintegrating tablet?

Yes. Its low dose makes an ODT technically feasible, but taste masking, content uniformity, mechanical strength, packaging, and disintegration performance require careful development.

Does bumetanide have biosimilar competition?

No. Bumetanide is a chemically synthesized small molecule. Generic-drug rules, not the biosimilar pathway, govern the principal U.S. competitive framework.

Can an oral bumetanide liquid command a premium price?

It can support differentiated pricing if it solves a defined administration problem, such as swallowing difficulty, feeding-tube use, or institutional dosing. Premium pricing is constrained by the availability of low-cost tablets and competing loop diuretics.

What is the most defensible commercial formulation for bumetanide?

A robust immediate-release, scored tablet is the lowest-risk platform. A stable unit-dose oral liquid or an administration-ready injectable may offer greater differentiation but carries higher development, manufacturing, and regulatory costs.

References

1. U.S. Food and Drug Administration. (n.d.). Bumex (bumetanide) prescribing information. DailyMed.
2. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book.
4. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs.
5. U.S. Food and Drug Administration. (2013). ANDA submissions: Content and format of abbreviated new drug applications.